NASDAQ:GLUE • US61225M1027
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MONTE ROSA THERAPEUTICS INC (GLUE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-14 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2026-01-08 | Guggenheim | Maintains | Buy -> Buy |
| 2026-01-08 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-16 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
| 2025-11-07 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-03-21 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-03-21 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-03-12 | LifeSci Capital | Initiate | Outperform |
| 2024-12-19 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2024-09-12 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-08-12 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-06-28 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-05-22 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-02-15 | Wedbush | Initiate | Outperform |
| 2023-10-19 | JP Morgan | Maintains | Overweight -> Overweight |
| 2023-08-11 | Credit Suisse | Reiterate | Neutral -> Neutral |
| 2023-05-12 | Credit Suisse | Reiterate | Neutral -> Neutral |
| 2023-03-17 | Credit Suisse | Maintains | Neutral |
| 2023-01-03 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
| 2022-10-13 | UBS | Initiate | Buy |
| 2022-08-15 | Jefferies | Initiate | Buy |
| 2022-05-12 | Piper Sandler | Maintains | Overweight |
| 2022-04-28 | Credit Suisse | Initiate | Neutral |
| 2022-02-10 | Wells Fargo | Initiate | Equal-Weight |
| 2021-10-14 | SVB Leerink | Initiate | Market Perform |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 75.622M | 139.16M 84.02% | 56.838M -59.16% | 66.334M 16.71% | 47.789M -27.96% | 72.444M 51.59% | 204.11M 181.75% | 692.43M 239.24% | 1.475B 113.02% | 2.217B 50.31% | |||
| EBITDA YoY % growth | -108.63M -53.54% | -137.089M -26.20% | -72.991M 46.76% | -41.82M 42.71% | 17.34M 141.46% | 108.12M 523.53% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -112.38M -54.20% | -143.311M -27.52% | -81.112M 43.40% | -34.827M 57.06% | -126.321M -262.71% | -150.099M -18.82% | -177.048M -17.95% | -226.894M -28.15% | -145.88M 35.71% | 314.56M 315.63% | 1.043B 231.57% | 1.74B 66.83% | |
| Operating Margin | N/A | N/A | -107.26% | -25.03% | -222.25% | -226.28% | -370.48% | -313.20% | -71.47% | 45.43% | 70.71% | 78.48% | |
| EPS YoY % growth | -2.29 20.50% | -2.64 -15.28% | -1.02 61.36% | -0.28 72.12% | -1.30 -357.03% | -1.61 -23.91% | -1.56 3.36% | -2.03 -30.28% | -1.10 45.67% | 3.77 442.59% | 11.05 192.84% | 17.08 54.55% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.36 -255.91% | -0.49 -186.63% | -0.50 -233.47% | -0.49 -47.19% | -0.47 -30.67% |
| Revenue Q2Q % growth | 15.816M -73.92% | 3.06M -96.40% | 3.315M -85.71% | 3.315M -74.04% | 3.392M -78.55% |
| EBITDA Q2Q % growth | -36.72M -273.82% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -30.239M -332.54% | -45.05M -202.30% | -49.47M -218.05% | -51.85M -57.24% | -51M -68.65% |
All data in USD
15 analysts have analysed GLUE and the average price target is 29.87 USD. This implies a price increase of 86.46% is expected in the next year compared to the current price of 16.02.
MONTE ROSA THERAPEUTICS INC (GLUE) will report earnings on 2026-05-06.
The consensus EPS estimate for the next earnings of MONTE ROSA THERAPEUTICS INC (GLUE) is -0.36 USD and the consensus revenue estimate is 15.82M USD.
The expected long term growth rate for MONTE ROSA THERAPEUTICS INC (GLUE) is 36.35%.